Trials / Completed
CompletedNCT02252653
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,010 (actual)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the frequency of TTR mutations in subjects suspected of having cardiac amyloidosis
Conditions
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2016-01-01
- Completion
- 2016-03-01
- First posted
- 2014-09-30
- Last updated
- 2016-07-20
Locations
58 sites across 6 countries: United States, Belgium, Brazil, France, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02252653. Inclusion in this directory is not an endorsement.